FDA allows standalone use of nasal spray antidepressant Spravato (esketamine)

Spravato, the brand name for esketamine, has a newly approved indication for treatment-resistant depression.

The FDA says esketamine, an antidepressant derived from the anesthetic and party drug ketamine, can now be prescribed on its own. It was approved in 2019 to treat severe depression.

(Image credit: tadamichi/Getty Images/iStockphoto)

  • Related Posts

    WATCH: Dog saved in icy river rescue

    Chris MacRitchie plunged himself into a frozen river in Vermont after realizing a dog had fallen through the ice.

    WATCH: Donald, Melania Trump visit the Bidens at the White House

    The president-elect and his wife were greeted by Joe Biden and first lady Jill Biden.

    Leave a Reply

    Your email address will not be published. Required fields are marked *